Zogenix (NASDAQ: ZGNX) is a private, specialty pharmaceutical company focused on the development and commercialization of medicines in neurology and pain. The company's portfolio includes sumatriptan DosePro - a needle-free, single-use, easy-to-use subcutaneous delivery system for sumatriptan and a late-stage controlled release opioid product utilizing the Elan SODAS technology.
Zogenix has filed 95 patents.
Serotonin receptor agonists, Substituted amphetamines, Stimulants, Designer drugs, Combination drugs
Serotonin receptor agonists, Substituted amphetamines, Stimulants, Designer drugs, Combination drugs
Latest Zogenix News
Feb 7, 2024
Delveinsight Business Research LLP The Dravet Syndrome market is experiencing a transformative shift driven by advancements in understanding the disorder’s underlying mechanisms and targeted therapeutic approaches. With a growing emphasis on precision medicine, there’s a notable trend toward personalized treatment strategies tailored to the unique genetic and clinical profiles of individual patients. This evolution is further propelled by ongoing research efforts aimed at identifying novel therapeutic targets and developing innovative interventions to address the complex needs of individuals living with Dravet Syndrome. DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dravet Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan). The report covers emerging Dravet Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dravet Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. Dravet Syndrome: An Overview According to the National Organization for Rare Disorders (NORD), Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems. Dravet Syndrome Foundation, states that Dravet Syndrome is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. Three stages usually associated with Dravet Syndrome are febrile, worsening, and stabilization. At present, there is no organizational or authoritative consensus on the diagnostic principles of Dravet Syndrome. Patient populations involving children are initially misdiagnosed, as the tests used to evaluate epilepsy, MRI, and EEG, appear normal at first instance in babies with Dravet syndrome. Dravet Syndrome Market Key Facts In 2022, total incident cases of Dravet Syndrome in the US have been estimated at around 21,760. In France, the total diagnosed cases of Dravet Syndrome have been estimated at around 1,050 cases in 2022, which is estimated to increase by 2032. According to the Dravet Syndrome Foundation (2022), a recent US epidemiology study concluded that Dravet Syndrome is twice as common as previously recognized, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation. As per the study by Gil-Nagel et al. (2019), the average incidence rate among pediatric and adult patients is 1.1 cases and 0.5 cases per million inhabitants, respectively in Spain. In the UK, total treated cases of Dravet Syndrome have been estimated at around 1,000 cases in 2022, which is estimated to increase by 2032. The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dravet Syndrome pipeline therapies. It also thoroughly assesses the Dravet Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics. The report gives complete details of the market trend for each marketed Dravet Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market. Dravet Syndrome Epidemiology Assessment The epidemiology section provides insights into the historical, current, and forecasted Dravet Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dravet Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. The Report Covers the Dravet Syndrome Epidemiology, Segmented as – Total Incident Cases of Dravet Syndrome in the 7MM [2019–2032] Total Diagnosed Cases of Dravet Syndrome in the 7MM Mutation-Specific Incident Cases of Dravet Syndrome in the 7MM [2019–2032] Age-specific Incident Cases of Dravet Syndrome in the 7MM [2019–2032] Gender-specific Incident Cases of Dravet Syndrome in the 7MM [2019–2032] Total Treated Cases of Dravet Syndrome in the 7MM [2019–2032] Dravet Syndrome Drugs Uptake and Pipeline Development Activities The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dravet Syndrome market or expected to be launched during the study period. The analysis covers the Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Dravet Syndrome drugs based on their sale and market share. The report also covers the Dravet Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dravet Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Learn How the Dravet Syndrome Market Will Evolve and Grow by 2032 @ Dravet Syndrome Therapeutics Analysis The available therapeutics treatment options in the Dravet Syndrome landscape aim to provide a cure to the patients suffering from this indication; however, there are several challenges that are yet to be tackled. Pharmaceutical companies have shifted their focus toward the current needs faced by Dravet Syndrome. There are some novel and strong emerging therapies that can change the treatment landscape of Dravet syndrome. Active Support from both organizations and pharma companies, which are rigorously working in order to find a better way to help the family with Dravet Syndrome. Efforts are made to increase awareness among people in collaboration with pharma companies. Currently, Takeda is leading the therapeutics market with its Dravet Syndrome drug candidates in the most advanced stage of clinical development. Dravet Syndrome Companies Actively Working in the Therapeutics Market Include Takeda Soticlestat: Takeda 4. Dravet Syndrome Market Overview at a Glance 5. Dravet Syndrome Disease Background and Overview 6. Dravet Syndrome Patient Journey 7. Dravet Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan) 8. Dravet Syndrome Treatment Algorithm, Current Treatment, and Medical Practices 9. Dravet Syndrome Unmet Needs 10. Key Endpoints of Dravet Syndrome Treatment 11. Dravet Syndrome Marketed Therapies 12. Dravet Syndrome Emerging Drugs and Latest Therapeutic Advances 13. Dravet Syndrome Seven Major Market Analysis 14. Attribute Analysis 16. Dravet Syndrome Companies Active in the Market 17. Dravet Syndrome Access and Reimbursement Overview 18. KOL Views on the Dravet Syndrome Market 19. Dravet Syndrome Market Drivers 20. Dravet Syndrome Market Barriers 21. Appendix 23. Disclaimer *The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents. Download the Sample PDF to Learn More About the Key Offerings of the Report @ About DelveInsight DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Other Trending Healthcare Reports by DelveInsight “Ductal Carcinoma in Situ Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Ductal Carcinoma in Situ market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Ductal Carcinoma in Situ market.a Media Contact
Zogenix Frequently Asked Questions (FAQ)
When was Zogenix founded?
Zogenix was founded in 2006.
Where is Zogenix's headquarters?
Zogenix's headquarters is located at 12671 High Bluff Drive, San Diego.
What is Zogenix's latest funding round?
Zogenix's latest funding round is Acq - P2P.
How much did Zogenix raise?
Zogenix raised a total of $199M.
Who are the investors of Zogenix?
Investors of Zogenix include UCB, Scale Venture Partners, Domain Associates, Life Science Angels, Clarus and 7 more.
Who are Zogenix's competitors?
Competitors of Zogenix include Zyla Life Sciences, Charleston Laboratories, Intarcia Therapeutics, Afferent Pharmaceuticals, Combinent BioMedical Systems and 7 more.
Compare Zogenix to Competitors
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.
Naryx Pharma is focused on development of its product candidates of inhaled, nebulized, intranasal drug formulations.
Orexo is a pharmaceutical company that focuses on the development of improved pharmaceuticals. The company's main offerings include innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Orexo primarily sells to the healthcare industry. It is based in Uppsala, Sweden.
Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.
Urigen Pharmaceuticals focuses on the development and commercialization of innovative products for urological indications within the healthcare sector. The company specializes in creating treatments aimed at alleviating the causes and symptoms of urological ailments, particularly Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). It is based in North Brunswick, New Jersey.